Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bioton Values Glaxo Deal at Up to $600 Million, CEO Tells Puls

Dec. 20 (Bloomberg) -- Bioton SA of Poland estimates the value of a distribution deal with GlaxoSmithKline Plc at as much as $600 million, Puls Biznesu reported, citing Bioton Chief Executive Officer Slawomir Ziegert.

Bioton announced the 15-year agreement, under which the U.K.-based company will distribute the Polish producer’s insulin in Russia, in a regulatory statement on Dec. 18.

To contact the reporter on this story: Pawel Kozlowski in Warsaw

To contact the editor responsible for this story: Gavin Serkin at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.